OCDX - OCDX STOCK NEWS

Quidel Corporation (NASDAQ: QDEL) has announced a definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share, totaling approximately $6 billion. This acquisition, representing a 25% premium over Ortho's prior closing price, aims to enhance Quidel's diagnostic capabilities across over 130 countries. The transaction is expected to yield annual cost synergies of $90 million and revenue synergies exceeding $100 million by 2025, enhancing Quidel's product innovation and operational efficiency.

Ortho Clinical Diagnostics (Nasdaq: OCDX) will participate in the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, featuring a fireside chat at 3:30 PM ET. A live webcast and replay will be available on the company’s Investors page. Ortho is a leading in vitro diagnostics company, impacting over 800,000 patients daily with innovative testing solutions. The company has a rich history in diagnostics innovation, including groundbreaking HIV and COVID-19 tests.

Ortho Clinical Diagnostics reported a strong third quarter for 2021, with a 15.8% increase in revenue to $522.5 million, including a 14.8% rise in core revenue to $508.9 million. The company also achieved a remarkable 161.0% increase in operating income, reaching $54.0 million. GAAP net income was $14.7 million, or $0.06 per diluted share, while adjusted net income was $50.9 million, or $0.21 per diluted share. The company raised its 2021 fiscal guidance, expecting $2.00 - $2.02 billion in core revenue, driven by strong performance across geographic regions.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) will announce its third quarter 2021 results on November 3, 2021, after market close. The company will host a conference call at 5:00 pm ET the same day to discuss the results, accessible via its website or by phone using Conference ID 5927918. A replay will be available shortly after the event. As a leader in in vitro diagnostics, Ortho serves over 800,000 patients daily and offers innovative solutions to enhance healthcare efficiency and outcomes.

Ortho Clinical Diagnostics Holdings (Nasdaq: OCDX) has been ranked No. 1 in the diagnostics industry for its Ortho Care™ Service and Support program during the 2021 IMV ServiceTrak™ Awards, marking the sixth consecutive year. This ranking results from interviews with over 2,000 laboratory professionals. Ortho also led in categories like Customer Satisfaction and Overall System Performance. The company emphasizes a strong customer focus and provides comprehensive service, ensuring efficient lab operations. This recognition highlights Ortho's commitment to customer service and innovation in the IVD sector.

Ortho Clinical Diagnostics (NASDAQ: OCDX) has launched the Immediate Spin Crossmatch (ISXM) capability on its ORTHO VISION® and ORTHO VISION® MAX analyzers, enhancing blood transfusion safety. This serological test detects ABO blood type incompatibility, crucial for preventing transfusion errors, which the National Center for Biotechnology Information highlights as a leading cause of transfusion-related fatalities. The ISXM addition reflects customer demand for improved workflow, allowing labs to focus on critical tasks. Ortho's commitment to innovation continues to impact over 800,000 patients daily.

Ortho Clinical Diagnostics Holdings announces the closing of a secondary offering of 25.3 million ordinary shares at $17.50 each, fully exercising underwriters' option for an additional 3.3 million shares. The offering was initiated by a shareholder affiliated with The Carlyle Group, resulting in Ortho no longer being classified as a "controlled company" under NASDAQ rules. The company itself did not sell any shares and received no proceeds. Goldman Sachs and J.P. Morgan acted as lead managers of the offering.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) announced a secondary offering of 22 million ordinary shares priced at $17.50 each, set to close on September 14, 2021. The shares are being sold by a shareholder affiliated with The Carlyle Group. Ortho will not receive proceeds from this offering and will cover certain costs associated with the sale. The underwriters have a 30-day option to purchase 3.3 million additional shares. Key financial firms are involved as book-running managers for the offering.

Ortho Clinical Diagnostics (Nasdaq: OCDX) announced a secondary offering of 22,000,000 ordinary shares by an affiliate of The Carlyle Group. The Selling Shareholder may also offer an additional 3,300,000 shares through underwriters Goldman Sachs and J.P. Morgan. Importantly, the company is not selling any shares and will not receive proceeds from the offering, instead covering associated costs. The registration statement has been filed with the SEC but is not yet effective.